* TROPHOS *
1999 - Méditerranée
Marseille
www.trophos.com Discovery, Drugs
Key words: Embryonic neurones, Parkinson's diseases, Huntington's diseases, Cardiac ischemia, IRIstop
Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection)
Clients: Prescribers
info@trophos.com
Age: 13 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo]
Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo]
Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre]
Fin.Dir.-CFO: Placet (Christine) [ex-Ernst & Young]
BusDev: Harris (Stephen) [Ph.D., ex-GSK]
Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels | Turnover (M€) : 0.01 (2009), 0.27 (2008), 0.68 (2006)
Total funding (M€) : 68.0
Last funding (M€) : 10.0
Focus : Multiple
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .12 | Financing : leader of new MitoCare consortium awarded 6 M€ by EU for POC study of novel cardioprotective compound, TRO40303 | RFIN | [11 years] |
| 2010 .10 | Clinical trial (Phase I) on TRO40303, in myocardial infarction (beginning), ended in February 2011 | CLIN | [11 years] |
| 2010 .09 | Financing : 10.0 M€ from Actelion (Switzerland) against minority share, with rights of full acquisition up to 2012 depending on phase III clinical results of olesoxime | RFIN | [11 years] |
| 2010 .03 | Clinical trial (phase III) for olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) (end recruitment) | CLIN | [11 years] |
| 2010 .03 | Launch : new web site on Charcot disease for patients and health professionals at MitoTarget | MKTG | [11 years] |
| 2009 .09 | Clinical trial planned, after first preclinical trial results on TRO40303, a novel TSPO ligand, significantly reducing myocardial infarct size | CLIN | [10 years] |
| 2009 .03 | Financing (grant over 3 years) : 6.7 M€ by Association Française contre les Myopathies (AFM), for further clinical development of lead drug candidate olesoxime (TRO19622) as a treatment for Spinal Muscular Atrophy | RFIN | [10 years] |
| 2008 .12 | Financing (no interest loan) : 6.0 M€, by the European Commission, to boost TRO19622 programs for ALS, within Trophos led consortium (Mitotarget) | DEBT | [9 years] |
| 2008 .06 | Nomination : Damian Marron as CEO, replacing co-founder Antoine Béret [born 1944, ex-Immunotech] who retires | ORGN | [9 years] |
| 2008 .02 | Financing (no interest loan) : 1.0 M€, by ANR, to support the project named IRIstop | DEBT | [9 years] |
| 2007 .09 | 3rd round-financing : 8.5 M€, led by OTC Asset Management with CM-CIC Asset Management and previous shareholders | RFINC | [8 years] |
| 2003 .04 | 2nd round-financing : 6.4 M€, led by Innoveris and previous shareholders | RFINB | [4 years] |
| 1999 .01 | Company founded by Antoine Béret (CEO), Michel Deléage (venture capitalist, died in 2011), and 3 scientists (as consultants) | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
